2023
336-OR: Insulin Delivery Modality Does Not Impact Glycemic Change during Physical Activity in Youth with Type 1 Diabetes (T1D)—Results from the Real-World T1DEXI Pediatric Study
RIDDELL M, BERGFORD S, GAL R, PATTON S, CLEMENTS M, CALHOUN P, SHERR J. 336-OR: Insulin Delivery Modality Does Not Impact Glycemic Change during Physical Activity in Youth with Type 1 Diabetes (T1D)—Results from the Real-World T1DEXI Pediatric Study. Diabetes 2023, 72 DOI: 10.2337/db23-336-or.Peer-Reviewed Original ResearchInsulin delivery modalitiesPre-exercise glucoseJuvenile Diabetes Research FoundationPediatric studiesGlucose levelsDelivery modalitiesSpeakers bureauType 1 diabetesBlood glucose levelsInsulin delivery methodsNIH National InstituteAdvisory PanelGlycemic changesContinuous glucose monitorHarry B. Helmsley Charitable TrustPhysical activityExercise typeType 1Activity monitorDiabetesNovo NordiskEli LillyLeona M.Helmsley Charitable TrustT1D.575-P: Do Overnight Dips Exist following Afternoon Exercise? Factors Associated with Nocturnal Hypoglycemia in the Type 1 Diabetes Exercise Initiative Pediatric (T1DexiP) Study
SHERR J, BERGFORD S, PATTON S, CLEMENTS M, CALHOUN P, GAL R, RIDDELL M. 575-P: Do Overnight Dips Exist following Afternoon Exercise? Factors Associated with Nocturnal Hypoglycemia in the Type 1 Diabetes Exercise Initiative Pediatric (T1DexiP) Study. Diabetes 2023, 72 DOI: 10.2337/db23-575-p.Peer-Reviewed Original ResearchAfternoon exerciseJuvenile Diabetes Research FoundationNocturnal hypoglycemiaAid useSpeakers bureauMeasures logistic regressionMin/dayNIH National InstituteBedtime glucoseMedian TBRNocturnal glycemiaAdvisory PanelHypoglycemia riskContinuous glucose monitorExercise sessionsHarry B. Helmsley Charitable TrustGlucose levelsHeart rateLower riskType 1Activity monitorLogistic regressionBiphasic patternInsulin deliveryNovo Nordisk
2022
100-LB: Glycemic Control Using Recommended Settings in Youth and Adults with Type 1 Diabetes (T1D) —Minimed 780G System with the Calibration-Free Guardian 4 Sensor Results
VIGERSKY R, BODE B, BRAZG R, BUCKINGHAM B, CARLSON A, KAISERMAN K, KIPNES M, LILJENQUIST D, PHILIS-TSIMIKAS A, PIHOKER C, POP-BUSUI R, REED J, SHERR J, SHULMAN D, SLOVER R, THRASHER J, CHEN X, LIU M, CORDERO T, VELLA M, RHINEHART A, SHIN J. 100-LB: Glycemic Control Using Recommended Settings in Youth and Adults with Type 1 Diabetes (T1D) —Minimed 780G System with the Calibration-Free Guardian 4 Sensor Results. Diabetes 2022, 71 DOI: 10.2337/db22-100-lb.Peer-Reviewed Original ResearchMannKind CorporationSpeakers bureauKidney diseaseNovo NordiskEli LillyAdvisory PanelNational InstituteHealth researchMonths of useEffectiveness endpointReata PharmaceuticalsGlycemic controlPivotal trialsSevere hypoglycemiaEffectiveness outcomesGlycemic metricsDiabetesBayer AGHealth groupsRoche DiagnosticsUnitedHealth GroupLexicon PharmaceuticalsMiniMedTarget rangeSanofi
2021
70-OR: Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D)
SHERR J, BODE B, FORLENZA G, LAFFEL L, BROWN S, BUCKINGHAM B, CRIEGO A, DESALVO D, MACLEISH S, HANSEN D, LY T. 70-OR: Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D). Diabetes 2021, 70 DOI: 10.2337/db21-70-or.Peer-Reviewed Original ResearchDiabetes careDiabetic ketoacidosisStandard therapySevere hypoglycemiaSpeakers bureauEli LillyYoung childrenPrimary safety outcomePrimary effectiveness outcomeSerious adverse eventsAdvisory PanelLexicon PharmaceuticalsDaily dose requirementsType 1 diabetesNovo NordiskBoehringer Ingelheim PharmaceuticalsMannKind CorporationPermissive hyperglycemiaBaseline characteristicsHybrid closed-loop systemT1D durationAdverse eventsGlucose targetsEfficacy analysisInsulin delivery systems
2018
Increased HbA1c Variability May Shorten Time to Microalbuminuria Development in Type 1 Diabetes (T1D)
CLEMENTS M, WU M, FOSTER N, LAFFEL L, SHAH V, VENDRAME F, KINGMAN R, ALONSO G, CARLSON A, DESALVO D, BUCKINGHAM B, SHERR J, BENJAMIN R, EYTH E, DUBOSE S. Increased HbA1c Variability May Shorten Time to Microalbuminuria Development in Type 1 Diabetes (T1D). Diabetes 2018, 67 DOI: 10.2337/db18-26-lb.Peer-Reviewed Original ResearchRisk of microalbuminuriaSD HbA1cDiabetes careT1D Exchange Clinic RegistryShorter diabetes durationSpeakers bureauType 1 diabetesAge of diagnosisEli LillyBoehringer Ingelheim PharmaceuticalsAdvisory PanelMannKind CorporationMicroalbuminuria developmentSanofi USDiabetes durationMean HbA1cT1D durationRenal diseaseClinic registryRegistry enrollmentClinic visit recordsT1D populationMedian numberMicroalbuminuriaDiabetes Institute